sunbet

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
×Ô¾õÐÔSLEСÊóÄ£×Ó
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > ÄÚÉøÍ¸¼°´úлÐÔ¼²²¡Ä£×Ó > ×Ô¾õÐÔSLEСÊóÄ£×Ó

ǰÑÔ

ϵͳÐÔºì°ßÀÇ´¯(systemic lupus erythematosus,SLE)ÊÇÒ»ÖÖ×ÔÉíÃâÒ߽鵼µÄ£¬ÒÔÃâÒßÐÔÑ×֢Ϊͻ³öÌåÏֵģ¬ÀÛ¼°¶àϵͳ¡¢¶àÆ÷¹Ù¡¢¶à×éÖ¯Ë𺦵ÄÂýÐÔÈ«ÉíÐÔ¼²²¡¡£ÑªÇåÖб£´æÒÔ¿¹ºË¿¹Ìå¡¢¿¹dsDNA¿¹ÌåΪ´ú±íµÄ¶àÖÖ×ÔÉí¿¹Ìå¡£ÁÙ´²ÌåÏÖΪºã¾ÃµÍ¡¢Öжȷ¢ÈÈ£¬·¦Á¦¡¢ÌåÖØ¼õÇá£¬Ãæ¼Õ²¿µûÐκì°ß£¬ÊàŦÌÛÍ´£¬ÐİüÑ×£¬¼äÖÊÐÔ·ÎÑ×£¬ÀÇ´¯ÐÔÉöÑס¢Éñ¾­ÏµÍ³¸Ä±äµÈÈ«ÉíÐÔÖ¢×´¡£»¯Ñé¼ì²éѪºìÂѰ×Ͻµ£¬°×ϸ°û»òѪС°åïÔÌ­£¬»¼ÕßѪÇå¿É²éµ½¶àÖÖ¿¹ºË¿¹Ìå¡¢¿¹Á×Ö¬¿¹ÌåºÍ¿¹×é֯ϸ°û¿¹Ì塣ѪÇå×ܲ¹Ì庬ÃÍϽµ£¬ÓÈÆäÊÇC3º¬Á¿µÍÏÂÌåÏÖΪÔ˶¯ÆÚ¡£

SLEÊÇÒ»ÖÖ³£¼ûµÄÄÑÖÎÐÔ¼²²¡£¬ËäÈ»ÏÖÒÑÃ÷È·SLEÊÇÒ»ÖÖ×ÔÉíÃâÒß²¡£¬µ«È·Çв¡ÒòºÍ·¢²¡»úÖÆÉÐδÍêÈ«ÆÊÎö¡£Ò»Ñùƽ³£ÒÔΪÖ÷ÒªÓëÒÅ´«ÓйØ£¬ÇéÐÎÒòËØÊÇÒ»¸ö´ÎÒªÒòËØ¡£ÓÉÓÚSLE»¼ÕßÅ®ÐÔÏÔ×ŶàÓÚÄÐÐÔ(9:1),XȾɫÌå±àÂëµÄ»ùÒò¿ÉÄÜÓë´Ë²¡ÓйØ¡£ÕýÓÉÓÚÔÆÔÆ£¬ÔËÓÃÖÖÖÖ¶¯ÎïÄ£×Ó´Ó²î±ð½Ç¶È¶Ô̽ÌÖ±¾²¡µÄ·¢²¡»úÖÆ¡¢²¡Àíת±äºÍÖÎÁÆÒªÁì¾ßÓÐÖ÷ÒªÒâÒå¡£

SLE¶¯ÎïÄ£×Ó¿É·ÖΪÓÕ·¢ÐÔ¶¯ÎïÄ£×Ó¡¢×Ô¾õÐÔ¶¯ÎïÄ£×ӺͻùÒòÐÞÊζ¯ÎïÄ£×Ó3Àà¡£

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯ÎСÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

NZB/BlNJСÊó×Ô¼º¾ßÓÐһЩ×ÔÉíÃâÒßÒì³££¬ÈçÈÜѪÐÔѪÐé¡¢ÃâÒßÇòÂѰ׺¬Á¿Ôö¸ß¡¢¿¹ºË¿¹Ìå¡¢¿¹DNA¿¹Ìå¡¢¿¹ÐØÏÙ¿¹ÌåºÍÃâÒ߸´ºÏÎïÐÔÉöСÇòÉöÑ×£»NZW/LacJСÊóÔòÒ»Ñùƽ³£Õý³££¬µ«ÀÏÁäÊó·ºÆð¿¹DNA¿¹ÌåºÍÉöÑס£µ±´ÆÐÔNZB/BlNJÓëÐÛÐÔNZW/LacJÔÓ½»£¬±¬·¢µÄF1´úÓÐÏÔ×Å×ÔÉíÃâÒßÐÔ¼²²¡£¬ÀàËÆÈ˵ÄSLE¡£

¡¾ÔìÄ£ÒªÁì¡¿£º

NZBWF1/JСÊóÊÇÓÉ´ÆÐÔNZB/ BlNJÓëÐÛÐÔNZW/LacJ½»Å䱬·¢µÄF1´ú¡£

¡¾Ä£×ÓÌØµã¡¿£º

NZBWF1/JСÊ󱬷¢µÄ×ÔÉíÃâÒßÐÔ¼²²¡ÀàËÆÈ˵ÄϵͳÐÔºì°ßÀÇ´¯£¬ÆäÌØÕ÷ÊǸߵζȵĿ¹ºË¿¹Ìå¡¢ÈÜѪÐÔѪÐé¡¢ÂѰ×Äò¡¢¾ÙÐÐÐÔÃâÒ߸´ºÏÎïÐÔÉöСÇòÉöÑס£´ÆÐԵķ¢²¡ÂʺÍÖ¢×´ÑÏÖØË®Æ½Ô½·¢ÏÔ×Å¡£

26£¥µÄF1´úСÊóÓе䷶µÄÀÇ´¯Ï¸°û£¬ÐÎ̬ѧÉÏÓëÈ˵Ļù±¾Ò»Ö¡£ÀÇ´¯Ï¸°û×îÔç·ºÆðÔÚ5ÔÂÁ䣬´ó´ó¶¼·ºÆðÔÚ6~9ÔÂÁ䣬´ÆÐÔ(48%)·ºÆðÀÇ´¯Ï¸°ûµÄ±ÈÀý¸ßÓÚÐÛÐÔ(2%)¡£ÁíÍ⣬44%µÄСÊóÓе䷶µÄÔ²µÄËÕÄ¾ËØÐ¡Ì壬×îÔç¿ÉÔÚ2ÔÂÁäʱÊӲ쵽¡£

ÈÜѪÐÔѪÐé¼ûÓÚ8ÔÂÁäÒÔÉÏÍíÄêÊó¡£39£¥ÐÛÐÔºÍ57£¥´ÆÐÔ×îСѪϸ°û±ÈÈÝСÓÚ40%£¬×îµÍÖÁ21%£¬²¢ÓëÑÏÖØÉö²¡ÓйØ¡£80£¥ÔÓ½»ÊóÓÐÂѰ×Äò£¬ÆäÖÐ40£¥Îª4£«ÂѰ×Äò£¬ÇÒ´ó¶¼Îª´ÆÐÔ¡£ÐÛÐÔ´ó¶àΪÖеȶÈÂѰ×Äò£¬ÏÔ΢¾µ¼ì²éÄò³Áµí͸Ã÷¹ÜÐͺÍϸ¿ÅÁ£¹ÜÐÍ¡£

ÀÇ´¯ÐÔÉö²¡ÌåÏÖΪÉöСÇò»ùµ×ĤÔöºñ¡¢ËÕÄ¾ËØÐ¡Ìå¡¢Ôî×´»µËÀ£»PAS·´Ó¦ÑôÐÔ¡£Ó«¹âÃâÒßÊÖÒÕÕ¹ÏÖÉöСÇò»ùµ×Ĥ´ó×ÚСÊóγÇòÂѰ׳Á»ý£»µç×ÓÏÔ΢¾µÏÔʾµä·¶µÄÈËÀÇ´¯ÐÔÉö²¡£¬ÉÏÆ¤×ãϸ°ûÈںϣ¬Ã«Ï¸Ñª¹Ü»ùµ×ĤÁ½²àÏËάÑùÄÚÆ¤Ï³Á»ý£¬ÄÚÆ¤Ï¸°ûÏÔ×ÅÖ×ÕÍ¡£ÀÇ´¯ÐÔÉö²¡ÖÐ50£¥ÎªÑÏÖØË®Æ½£¬ÇÒ´ó¶àΪ´ÆÐÔ¡£

ÀÇ´¯ÐÔÉö²¡Ð¡ÊóÖÐѪÇåÇåÂѰ׽µµÍ£¬α1ÇòÂѰ×ÏÔÖøÉý¸ß£»Éö²¡ºóÆÚСÊóѪÄòËØµª¡¢µ¨¹Ì´¼Éý¸ß¡£46£¥µÄF1´úÓп¹ºË¿¹Ìå¡£

ÆäËûµÄ²¡±äÓУº24£¥µÄСÊóÓм±ÐÔºÍÂýÐÔ¸ÎÑ×£¬ÓëÈËÔçÆÚÀÇ´¯Ñù¸ÎÑ×ÏàËÆ¡£µ¥¸ö¸Îϸ°û»µËÀ£¬¶àÐÎ̬ºËºÍÁܰÍϸ°û½þÈ󣬱¬·¢¸¹Ë®£»26£¥Ð¡ÊóÓÐÆæÒìµÄÆ¢ÏËά»¯£¬ÔÚ°×ËèµÄ±ßÑØ×îÏÈ£¬ÑÏÖØ²¡ÀýÏËά»¯Ìæ»»Õû¸öÆ¢ÔàʵÖÊ¡£

NZBWF1ÓëÈËSLE²î±ðÖ®´¦ÔÚÓÚûÓÐÆ¤·ô»òÊàŦµÄ²¡Àí¸Ä±ä¡£½«ÌêëƤ·ô̻¶ÓÚÈÈʯӢ×ÏÍâÏßδÄÜÓÕ·¢ÀÇ´¯Ñù²¡±ä¡£

¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º

×Ô¾õÐÔSLEÄ£×Ó¶àÊÇСÊ󣬯äÖÐNZBWF1/JСÊóÊǺÜÊǾ­µäµÄSLEÄ£×Ó£¬´ó¶¼Ñ§ÕßÒÔΪNZBWF1/JСÊó×î¿¿½üÓÚÈËÀàSLE,ÊÇÑо¿SLE×î¾­µäµÄ¶¯ÎïÄ£×Ó¡£×Ô1960ÄêÔ³õÒÔÀ´£¬ÒѾ­±»ÆÕ±éÓÃ×÷Ϊ×ÔÉíÃâÒßÐÔ¼²²¡µÄÑо¿£¬²»µ«ÆÊÎöÖØ´óµÄÃâÒßÉúÎï·´Ó¦ºÍ»úÖÆ£¬²¢ÇÒÆÊÎö¶àÒòËØ¼²²¡µÄÖØ´óÒÅ´«»ù´¡£¬¿ÉÓÃÓÚSLE²¡Òò¡¢·¢²¡»úÀí¡¢×ÔÉíÃâÒßÐÔ¼²²¡µÄÃâÒßµ÷Àí¡¢ÃâÒ߸´ºÏÎïÐÔÉöÑ×£¬ÖÎÁÆSLEÒ©ÎïµÄҩЧѧÑо¿µÈ¡£´ËÄ£×ÓÖ»ÓÃF1´ú¡£

NZBWF1/JСÊóÓиߵζȵĿ¹dsDNA¿¹Ì壬·¢²¡ÓÐÏÔ×ŵÄÐÔ±ð²î±ð£¬´ÆÐÔ·¢²¡Ô磬¶àÔÚ12¸öÔÂËÀÓÚÉöСÇòÉöÑס£ÐÛÊó¶àÔÚ15~20¸öÔÂÁäʱËÀÓÚÂýÐÔ¾ÙÐÐÐÔÉöÑס£±ðµÄ£¬´Æ¼¤ËؿɼӾ粡Ç飬¶øÐÛ¼¤ËؿɼõÇáÆä²¡Çé¡£

 

²Î¿¼ÎÄÏ×£º

1.¬ÁÕ£¬ÞÉ»ª¹ú£¬ÎâºñÉú£®»î»¯ÁܰÍϸ°û¼°ÆäȾɫÖÊÓÕµ¼¿¹ºË¿¹ÌåÌìÉú£®ÖлªÎ¢ÉúÎïѧºÍÃâÒßѧÔÓÖ¾£¬1999, 19(1):44-46

2.Àî½ðÖ¦£¬¶¡öÁ£¬Merim Boukherouba£¬µÈ£®PristaneÓÕµ¼Ð¡ÊóϵͳÐÔºì°àÀÇ´¯¶¯ÎïÄ£×ÓµÄÑо¿£®Ï¸°ûÓë·Ö×ÓÃâÒßѧÔÓÖ¾£¬2011,27(2): 119-122

3.ÂÞÑåÑ壬ÁÖÓÐÀ¤£¬»Æ´äÀö£¬µÈ£®¸Îϸ°ûÖÊÂѰ×ÓÕµ¼ÏµÍ³ÐÔºì°ßÀÇ´¯ÍÃÄ£×ÓµÄʵÑéÑо¿. ÃâÒßѧÔÓÖ¾£¬2011,27 (8):710-714

4.Bubier JA,Sproule TJ,Foreman  O,el al.  A  critical role for TL-21 receptor signaling in the pathogenesis of systemic lupus erythemalosus in BXSB-Yaa mice. Proc Natl Acad Sci U S A,2009, 106(5): 1518-1523

5.Chen J, Kubalak SW, Chien KR. Ventricular muscle­restricted targeting of the RXRalpha gene reveals a non-cell-autonomous requirement in cardiac chamber morphogenesis. Development, 1998, 125 (10): 1943-1949

6.Dubois EL,Horowitz RE,Demopoulos HB,et al. NZB/ NZW mice as a model of systemic lupus erythematosus£®JAMA, 1966, 195 (4):285-289

7.Han B,Moore PA, Wu J,et al. Overexpression of human decoy receptor 3 in mice results in a systemic lupus erythematosus­like synclrome. Arthritis Rheum, 2007,56 (11):3748-3758

8.Satoh M. Richards HB, Shaheen VM, et al. Widespread susceptibility among inbred mouse strains to the induction of lupus autoanlibodies by pristane. Clin Exp lmmunol, 2000, 121(2):399-405

9.Satoh M, Reeves WH. Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristine. J Exp Med, 1994, 180 (6):2341-2346

10.Takai T, Ono M, Hikida M, et al. Augmented humoral and anaphylaclic responses in Fc gamma R¢ò-deficienl mice. Nature, 1996,379(6563):346-349

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Ä£×ÓĿ¼
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > ÄÚÉøÍ¸¼°´úлÐÔ¼²²¡Ä£×Ó > ×Ô¾õÐÔSLEСÊóÄ£×Ó
×Ô¾õÐÔSLEСÊóÄ£×Ó

ǰÑÔ

ϵͳÐÔºì°ßÀÇ´¯(systemic lupus erythematosus,SLE)ÊÇÒ»ÖÖ×ÔÉíÃâÒ߽鵼µÄ£¬ÒÔÃâÒßÐÔÑ×֢Ϊͻ³öÌåÏֵģ¬ÀÛ¼°¶àϵͳ¡¢¶àÆ÷¹Ù¡¢¶à×éÖ¯Ë𺦵ÄÂýÐÔÈ«ÉíÐÔ¼²²¡¡£ÑªÇåÖб£´æÒÔ¿¹ºË¿¹Ìå¡¢¿¹dsDNA¿¹ÌåΪ´ú±íµÄ¶àÖÖ×ÔÉí¿¹Ìå¡£ÁÙ´²ÌåÏÖΪºã¾ÃµÍ¡¢Öжȷ¢ÈÈ£¬·¦Á¦¡¢ÌåÖØ¼õÇá£¬Ãæ¼Õ²¿µûÐκì°ß£¬ÊàŦÌÛÍ´£¬ÐİüÑ×£¬¼äÖÊÐÔ·ÎÑ×£¬ÀÇ´¯ÐÔÉöÑס¢Éñ¾­ÏµÍ³¸Ä±äµÈÈ«ÉíÐÔÖ¢×´¡£»¯Ñé¼ì²éѪºìÂѰ×Ͻµ£¬°×ϸ°û»òѪС°åïÔÌ­£¬»¼ÕßѪÇå¿É²éµ½¶àÖÖ¿¹ºË¿¹Ìå¡¢¿¹Á×Ö¬¿¹ÌåºÍ¿¹×é֯ϸ°û¿¹Ì塣ѪÇå×ܲ¹Ì庬ÃÍϽµ£¬ÓÈÆäÊÇC3º¬Á¿µÍÏÂÌåÏÖΪÔ˶¯ÆÚ¡£

SLEÊÇÒ»ÖÖ³£¼ûµÄÄÑÖÎÐÔ¼²²¡£¬ËäÈ»ÏÖÒÑÃ÷È·SLEÊÇÒ»ÖÖ×ÔÉíÃâÒß²¡£¬µ«È·Çв¡ÒòºÍ·¢²¡»úÖÆÉÐδÍêÈ«ÆÊÎö¡£Ò»Ñùƽ³£ÒÔΪÖ÷ÒªÓëÒÅ´«ÓйØ£¬ÇéÐÎÒòËØÊÇÒ»¸ö´ÎÒªÒòËØ¡£ÓÉÓÚSLE»¼ÕßÅ®ÐÔÏÔ×ŶàÓÚÄÐÐÔ(9:1),XȾɫÌå±àÂëµÄ»ùÒò¿ÉÄÜÓë´Ë²¡ÓйØ¡£ÕýÓÉÓÚÔÆÔÆ£¬ÔËÓÃÖÖÖÖ¶¯ÎïÄ£×Ó´Ó²î±ð½Ç¶È¶Ô̽ÌÖ±¾²¡µÄ·¢²¡»úÖÆ¡¢²¡Àíת±äºÍÖÎÁÆÒªÁì¾ßÓÐÖ÷ÒªÒâÒå¡£

SLE¶¯ÎïÄ£×Ó¿É·ÖΪÓÕ·¢ÐÔ¶¯ÎïÄ£×Ó¡¢×Ô¾õÐÔ¶¯ÎïÄ£×ӺͻùÒòÐÞÊζ¯ÎïÄ£×Ó3Àà¡£

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯ÎСÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

NZB/BlNJСÊó×Ô¼º¾ßÓÐһЩ×ÔÉíÃâÒßÒì³££¬ÈçÈÜѪÐÔѪÐé¡¢ÃâÒßÇòÂѰ׺¬Á¿Ôö¸ß¡¢¿¹ºË¿¹Ìå¡¢¿¹DNA¿¹Ìå¡¢¿¹ÐØÏÙ¿¹ÌåºÍÃâÒ߸´ºÏÎïÐÔÉöСÇòÉöÑ×£»NZW/LacJСÊóÔòÒ»Ñùƽ³£Õý³££¬µ«ÀÏÁäÊó·ºÆð¿¹DNA¿¹ÌåºÍÉöÑס£µ±´ÆÐÔNZB/BlNJÓëÐÛÐÔNZW/LacJÔÓ½»£¬±¬·¢µÄF1´úÓÐÏÔ×Å×ÔÉíÃâÒßÐÔ¼²²¡£¬ÀàËÆÈ˵ÄSLE¡£

¡¾ÔìÄ£ÒªÁì¡¿£º

NZBWF1/JСÊóÊÇÓÉ´ÆÐÔNZB/ BlNJÓëÐÛÐÔNZW/LacJ½»Å䱬·¢µÄF1´ú¡£

¡¾Ä£×ÓÌØµã¡¿£º

NZBWF1/JСÊ󱬷¢µÄ×ÔÉíÃâÒßÐÔ¼²²¡ÀàËÆÈ˵ÄϵͳÐÔºì°ßÀÇ´¯£¬ÆäÌØÕ÷ÊǸߵζȵĿ¹ºË¿¹Ìå¡¢ÈÜѪÐÔѪÐé¡¢ÂѰ×Äò¡¢¾ÙÐÐÐÔÃâÒ߸´ºÏÎïÐÔÉöСÇòÉöÑס£´ÆÐԵķ¢²¡ÂʺÍÖ¢×´ÑÏÖØË®Æ½Ô½·¢ÏÔ×Å¡£

26£¥µÄF1´úСÊóÓе䷶µÄÀÇ´¯Ï¸°û£¬ÐÎ̬ѧÉÏÓëÈ˵Ļù±¾Ò»Ö¡£ÀÇ´¯Ï¸°û×îÔç·ºÆðÔÚ5ÔÂÁ䣬´ó´ó¶¼·ºÆðÔÚ6~9ÔÂÁ䣬´ÆÐÔ(48%)·ºÆðÀÇ´¯Ï¸°ûµÄ±ÈÀý¸ßÓÚÐÛÐÔ(2%)¡£ÁíÍ⣬44%µÄСÊóÓе䷶µÄÔ²µÄËÕÄ¾ËØÐ¡Ì壬×îÔç¿ÉÔÚ2ÔÂÁäʱÊӲ쵽¡£

ÈÜѪÐÔѪÐé¼ûÓÚ8ÔÂÁäÒÔÉÏÍíÄêÊó¡£39£¥ÐÛÐÔºÍ57£¥´ÆÐÔ×îСѪϸ°û±ÈÈÝСÓÚ40%£¬×îµÍÖÁ21%£¬²¢ÓëÑÏÖØÉö²¡ÓйØ¡£80£¥ÔÓ½»ÊóÓÐÂѰ×Äò£¬ÆäÖÐ40£¥Îª4£«ÂѰ×Äò£¬ÇÒ´ó¶¼Îª´ÆÐÔ¡£ÐÛÐÔ´ó¶àΪÖеȶÈÂѰ×Äò£¬ÏÔ΢¾µ¼ì²éÄò³Áµí͸Ã÷¹ÜÐͺÍϸ¿ÅÁ£¹ÜÐÍ¡£

ÀÇ´¯ÐÔÉö²¡ÌåÏÖΪÉöСÇò»ùµ×ĤÔöºñ¡¢ËÕÄ¾ËØÐ¡Ìå¡¢Ôî×´»µËÀ£»PAS·´Ó¦ÑôÐÔ¡£Ó«¹âÃâÒßÊÖÒÕÕ¹ÏÖÉöСÇò»ùµ×Ĥ´ó×ÚСÊóγÇòÂѰ׳Á»ý£»µç×ÓÏÔ΢¾µÏÔʾµä·¶µÄÈËÀÇ´¯ÐÔÉö²¡£¬ÉÏÆ¤×ãϸ°ûÈںϣ¬Ã«Ï¸Ñª¹Ü»ùµ×ĤÁ½²àÏËάÑùÄÚÆ¤Ï³Á»ý£¬ÄÚÆ¤Ï¸°ûÏÔ×ÅÖ×ÕÍ¡£ÀÇ´¯ÐÔÉö²¡ÖÐ50£¥ÎªÑÏÖØË®Æ½£¬ÇÒ´ó¶àΪ´ÆÐÔ¡£

ÀÇ´¯ÐÔÉö²¡Ð¡ÊóÖÐѪÇåÇåÂѰ׽µµÍ£¬α1ÇòÂѰ×ÏÔÖøÉý¸ß£»Éö²¡ºóÆÚСÊóѪÄòËØµª¡¢µ¨¹Ì´¼Éý¸ß¡£46£¥µÄF1´úÓп¹ºË¿¹Ìå¡£

ÆäËûµÄ²¡±äÓУº24£¥µÄСÊóÓм±ÐÔºÍÂýÐÔ¸ÎÑ×£¬ÓëÈËÔçÆÚÀÇ´¯Ñù¸ÎÑ×ÏàËÆ¡£µ¥¸ö¸Îϸ°û»µËÀ£¬¶àÐÎ̬ºËºÍÁܰÍϸ°û½þÈ󣬱¬·¢¸¹Ë®£»26£¥Ð¡ÊóÓÐÆæÒìµÄÆ¢ÏËά»¯£¬ÔÚ°×ËèµÄ±ßÑØ×îÏÈ£¬ÑÏÖØ²¡ÀýÏËά»¯Ìæ»»Õû¸öÆ¢ÔàʵÖÊ¡£

NZBWF1ÓëÈËSLE²î±ðÖ®´¦ÔÚÓÚûÓÐÆ¤·ô»òÊàŦµÄ²¡Àí¸Ä±ä¡£½«ÌêëƤ·ô̻¶ÓÚÈÈʯӢ×ÏÍâÏßδÄÜÓÕ·¢ÀÇ´¯Ñù²¡±ä¡£

¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º

×Ô¾õÐÔSLEÄ£×Ó¶àÊÇСÊ󣬯äÖÐNZBWF1/JСÊóÊǺÜÊǾ­µäµÄSLEÄ£×Ó£¬´ó¶¼Ñ§ÕßÒÔΪNZBWF1/JСÊó×î¿¿½üÓÚÈËÀàSLE,ÊÇÑо¿SLE×î¾­µäµÄ¶¯ÎïÄ£×Ó¡£×Ô1960ÄêÔ³õÒÔÀ´£¬ÒѾ­±»ÆÕ±éÓÃ×÷Ϊ×ÔÉíÃâÒßÐÔ¼²²¡µÄÑо¿£¬²»µ«ÆÊÎöÖØ´óµÄÃâÒßÉúÎï·´Ó¦ºÍ»úÖÆ£¬²¢ÇÒÆÊÎö¶àÒòËØ¼²²¡µÄÖØ´óÒÅ´«»ù´¡£¬¿ÉÓÃÓÚSLE²¡Òò¡¢·¢²¡»úÀí¡¢×ÔÉíÃâÒßÐÔ¼²²¡µÄÃâÒßµ÷Àí¡¢ÃâÒ߸´ºÏÎïÐÔÉöÑ×£¬ÖÎÁÆSLEÒ©ÎïµÄҩЧѧÑо¿µÈ¡£´ËÄ£×ÓÖ»ÓÃF1´ú¡£

NZBWF1/JСÊóÓиߵζȵĿ¹dsDNA¿¹Ì壬·¢²¡ÓÐÏÔ×ŵÄÐÔ±ð²î±ð£¬´ÆÐÔ·¢²¡Ô磬¶àÔÚ12¸öÔÂËÀÓÚÉöСÇòÉöÑס£ÐÛÊó¶àÔÚ15~20¸öÔÂÁäʱËÀÓÚÂýÐÔ¾ÙÐÐÐÔÉöÑס£±ðµÄ£¬´Æ¼¤ËؿɼӾ粡Ç飬¶øÐÛ¼¤ËؿɼõÇáÆä²¡Çé¡£

 

²Î¿¼ÎÄÏ×£º

1.¬ÁÕ£¬ÞÉ»ª¹ú£¬ÎâºñÉú£®»î»¯ÁܰÍϸ°û¼°ÆäȾɫÖÊÓÕµ¼¿¹ºË¿¹ÌåÌìÉú£®ÖлªÎ¢ÉúÎïѧºÍÃâÒßѧÔÓÖ¾£¬1999, 19(1):44-46

2.Àî½ðÖ¦£¬¶¡öÁ£¬Merim Boukherouba£¬µÈ£®PristaneÓÕµ¼Ð¡ÊóϵͳÐÔºì°àÀÇ´¯¶¯ÎïÄ£×ÓµÄÑо¿£®Ï¸°ûÓë·Ö×ÓÃâÒßѧÔÓÖ¾£¬2011,27(2): 119-122

3.ÂÞÑåÑ壬ÁÖÓÐÀ¤£¬»Æ´äÀö£¬µÈ£®¸Îϸ°ûÖÊÂѰ×ÓÕµ¼ÏµÍ³ÐÔºì°ßÀÇ´¯ÍÃÄ£×ÓµÄʵÑéÑо¿. ÃâÒßѧÔÓÖ¾£¬2011,27 (8):710-714

4.Bubier JA,Sproule TJ,Foreman  O,el al.  A  critical role for TL-21 receptor signaling in the pathogenesis of systemic lupus erythemalosus in BXSB-Yaa mice. Proc Natl Acad Sci U S A,2009, 106(5): 1518-1523

5.Chen J, Kubalak SW, Chien KR. Ventricular muscle­restricted targeting of the RXRalpha gene reveals a non-cell-autonomous requirement in cardiac chamber morphogenesis. Development, 1998, 125 (10): 1943-1949

6.Dubois EL,Horowitz RE,Demopoulos HB,et al. NZB/ NZW mice as a model of systemic lupus erythematosus£®JAMA, 1966, 195 (4):285-289

7.Han B,Moore PA, Wu J,et al. Overexpression of human decoy receptor 3 in mice results in a systemic lupus erythematosus­like synclrome. Arthritis Rheum, 2007,56 (11):3748-3758

8.Satoh M. Richards HB, Shaheen VM, et al. Widespread susceptibility among inbred mouse strains to the induction of lupus autoanlibodies by pristane. Clin Exp lmmunol, 2000, 121(2):399-405

9.Satoh M, Reeves WH. Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristine. J Exp Med, 1994, 180 (6):2341-2346

10.Takai T, Ono M, Hikida M, et al. Augmented humoral and anaphylaclic responses in Fc gamma R¢ò-deficienl mice. Nature, 1996,379(6563):346-349

¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿